Cefdinir indications and usage: Difference between revisions
(Created page with "__NOTOC__ {{Meropenem}} {{CMG}} ==Cefdinir indications and usage== To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules a...") |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__{{Cefdinir}}{{CMG}} | ||
{{ | |||
{{CMG}} | |||
==Cefdinir indications and usage== | ==Cefdinir indications and usage== | ||
To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. | To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir [[capsules ]]and other antibacterial drugs, cefdinir [[capsules ]]should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. | ||
Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. | Cefdinir [[capsules ]]are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. | ||
Adults and Adolescents: | Adults and Adolescents: | ||
| Line 12: | Line 10: | ||
Community-Acquired Pneumonia: | Community-Acquired Pneumonia: | ||
Caused by Haemophilus influenzae (including | Caused by [[Haemophilus influenzae]] (including [[Beta-lactamase]] producing strains), [[Haemophilus parainfluenzae]] (including [[Beta-lactamase]] producing strains), [[Streptococcus pneumoniae ]] ([[penicillin]]-susceptible strains only), and [[Moraxella catarrhalis]] (including [[Beta-lactamase]] producing strains) (see CLINICAL STUDIES). | ||
Acute Exacerbations of Chronic Bronchitis: | Acute Exacerbations of Chronic Bronchitis: | ||
Caused by Haemophilus influenzae (including | Caused by [[Haemophilus influenzae]] (including [[Beta-lactamase]] producing strains), Haemophilus parainfluenzae (including [[Beta-lactamase]] producing strains), [[Streptococcus pneumoniae ]] ([[penicillin]]-susceptible strains only), and [[Moraxella catarrhalis]] (including [[Beta-lactamase]] producing strains). | ||
Acute Maxillary Sinusitis: | Acute Maxillary Sinusitis: | ||
Caused by Haemophilus influenzae (including | Caused by [[Haemophilus influenzae]] (including [[Beta-lactamase]] producing strains), [[Streptococcus pneumoniae ]] ([[penicillin]]-susceptible strains only), and [[Moraxella catarrhalis]](including [[Beta-lactamase]] producing strains). | ||
NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE AND ADMINISTRATION. | NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE AND ADMINISTRATION. | ||
| Line 28: | Line 26: | ||
Caused by Streptococcus pyogenes (see CLINICAL STUDIES). | Caused by Streptococcus pyogenes (see CLINICAL STUDIES). | ||
NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever followingS. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. | NOTE: Cefdinir is effective in the eradication of S. pyogenes from the [[oropharynx]]. Cefdinir has not, however, been studied for the prevention of rheumatic fever followingS. pyogenes pharyngitis/tonsillitis. Only intramuscular [[penicillin]] has been demonstrated to be effective for the prevention of rheumatic fever. | ||
Uncomplicated Skin and Skin Structure Infections: | Uncomplicated Skin and Skin Structure Infections: | ||
Caused by Staphylococcus aureus (including | Caused by Staphylococcus aureus (including [[Beta-lactamase]] producing strains) and Streptococcus pyogenes. | ||
Pediatric Patients: | Pediatric Patients: | ||
Acute Bacterial Otitis Media: | Acute Bacterial [[Otitis]] Media: | ||
Caused by Haemophilus influenzae (including | Caused by [[Haemophilus influenzae]] (including [[Beta-lactamase]] producing strains), [[Streptococcus pneumoniae ]] ([[penicillin]]-susceptible strains only), and [[Moraxella catarrhalis]](including [[Beta-lactamase]] producing strains). | ||
Pharyngitis/Tonsillitis: | Pharyngitis/Tonsillitis: | ||
| Line 44: | Line 42: | ||
Caused by Streptococcus pyogenes (see CLINICAL STUDIES). | Caused by Streptococcus pyogenes (see CLINICAL STUDIES). | ||
NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever followingS. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. | NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever followingS. pyogenes pharyngitis/tonsillitis. Only intramuscular [[penicillin]] has been demonstrated to be effective for the prevention of rheumatic fever. | ||
Uncomplicated Skin and Skin Structure Infections: | Uncomplicated Skin and Skin Structure Infections: | ||
Caused by Staphylococcus aureus (including | Caused by Staphylococcus aureus (including [[Beta-lactamase]] producing strains) and Streptococcus pyogenes.<ref>{{Cite web | last = |first = |title = http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/50739S2LBL.pdf |url =http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/50739S2LBL.pdf |publisher = |date = | accessdate = }}</ref> | ||
==References== | |||
{{Reflist}} | |||
{{FDA}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] | |||
Revision as of 20:12, 23 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Cefdinir indications and usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.
Adults and Adolescents:
Community-Acquired Pneumonia:
Caused by Haemophilus influenzae (including Beta-lactamase producing strains), Haemophilus parainfluenzae (including Beta-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including Beta-lactamase producing strains) (see CLINICAL STUDIES).
Acute Exacerbations of Chronic Bronchitis:
Caused by Haemophilus influenzae (including Beta-lactamase producing strains), Haemophilus parainfluenzae (including Beta-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including Beta-lactamase producing strains).
Acute Maxillary Sinusitis:
Caused by Haemophilus influenzae (including Beta-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis(including Beta-lactamase producing strains).
NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE AND ADMINISTRATION.
Pharyngitis/Tonsillitis:
Caused by Streptococcus pyogenes (see CLINICAL STUDIES).
NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever followingS. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.
Uncomplicated Skin and Skin Structure Infections:
Caused by Staphylococcus aureus (including Beta-lactamase producing strains) and Streptococcus pyogenes.
Pediatric Patients:
Acute Bacterial Otitis Media:
Caused by Haemophilus influenzae (including Beta-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis(including Beta-lactamase producing strains).
Pharyngitis/Tonsillitis:
Caused by Streptococcus pyogenes (see CLINICAL STUDIES).
NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever followingS. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.
Uncomplicated Skin and Skin Structure Infections:
Caused by Staphylococcus aureus (including Beta-lactamase producing strains) and Streptococcus pyogenes.[1]
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/50739S2LBL.pdf" (PDF). External link in
|title=(help)
Adapted from the FDA Package Insert.